Rajeshkumar Kedia

In case you have missed it! Let's have a glance at the Nifty 50 - Top gainers⬆️ & losers⬇️ in the limelight this week. . . . #MotilalOswal #paanchkapunch #stockmarket #stocksfor2022 #stockmarketindia #stockmarketinvesting #nifty50 #topstocksoftheweek #stockmarketinvesting #experttips #chooserightstocks #investmentadvice #stockrecommendations #stockratings #stockanalysis #marketanalysis #expertadvice #MotilalOswal #paanchkapunch #stockmarket #stocksfor2022 #stockmarketindia #stockmarketinvesting #nifty50 #topstocksoftheweek #experttips #chooserightstocks #investmentadvice #stockrecommendations #stockratings #stockanalysis #marketanalysis #expertadvice

1) The increasing dependency on tech due to the pandemic is resulting in better performance of IT stocks. The positive result of Accenture also resulted in fresh buying of tech stocks in Indian market. 2) Vodafone has won arbitration against India over the government's retro tax demand of Rs 20,000 crore at the Permanent Court of Arbitration in Hague on Friday. The Hague Court in its ruling said that the conduct of the Indian tax department is in breach of "fair and equitable" treatment. The Arbitration Tribunal has directed the Indian Tax Department to cease the conduct on the question. A failure to comply will engage its international responsibility. #MOMarketUpdates #MotilalOswal #Vodafone #ITstocks #Indianstockmarket #stockrecommendation #investingtips #NSE #BSE

As the world highly depends on technology during Covid-19, the technology stocks the IT stocks are gaining attention. HCL has hit a 52-week new high. #MOMarketUpdates #MotilalOswal #ITstocks #indianstockmarket #stockrecommendation #HCL #TCS

The Pharma stocks are positive due to multiple approvals of US FDA for different medicines. The companies are also manufacturing the drugs for the primary treatment of Covid-19. Dr Reddy's Laboratories reclaimed the tag of being the second most valuable listed pharmaceutical company. Sun Pharma is the most valued listed company of India with the market cap of Rs 1.26lakh cr. With a favourable ruling in the appeals court, the odds of launching gVascepa also rise considerably. Bristol Myers Squibb had inked a patent settlement with Dr. Reddy’s Laboratories, allowing the Indian generics company to start with a “volume-limited” launch sometime after March 2022. The exact date of the rollout, and amount of generic Revlimid Dr. Reddy’s will be allowed to sell, are confidential. But on January 31, 2026, the company will have a license to sell its generic Revlimid with no limits. #MOMarketUpdates #IndianStockMarket #MotilalOswal #NiftyPharma #NSE #BSE #Recommendation #Stocktip #Stockrecommendation